Plecanatide vs Pemvidutide
Head-to-head comparison of Plecanatide (Plecanatide) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | Pemvidutide |
|---|---|---|
| Category | Gastrointestinal | Weight Management |
| Full Name | Plecanatide | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | Approx. 1620 Da | N/A |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | Approximately 1 week |
| Amino Acids | 16 | N/A |
| Typical Dose | 3 mg once daily | Trial-dependent; once-weekly SC titration |
| Route | Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 18 |
| Research Status | Clinical | Clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.